Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women
Sponsor
Solvay Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT00141570
Collaborator
(none)
350
77
36
4.5
0.1
Study Details
Study Description
Brief Summary
To determine whether treatment with ESTRATEST® H.S. Tablets is superior to treatment with esterified estrogens tablets
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Study Design
Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
A Multi-Center, Double-Blind Study to Determine the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women
Study Start Date
:
Jun 1, 2004
Actual Primary Completion Date
:
Jun 1, 2007
Actual Study Completion Date
:
Jun 1, 2007
Outcome Measures
Primary Outcome Measures
- Change from baseline in the total score of the Menopause Rating Scale (MRS) at Week 12 []
Secondary Outcome Measures
- Change from baseline in the MRS at Week 12 & monthly change from baseline to Week 12 in the MENQOL; Comparison of changes in SHBG & testosterone & how these changes correlate with the MRS []
Eligibility Criteria
Criteria
Ages Eligible for Study:
30 Years
to 65 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Menopausal women between the ages of 30 and 65 years (inclusive) with symptoms of estrogen and/or androgen deficiency not currently controlled by estrogen therapy as determined by patient report and the Investigator's clinical judgement
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Site 66 | Huntsville | Alabama | United States | |
2 | Site 57 | Mobile | Alabama | United States | |
3 | Site 46 | Montgomery | Alabama | United States | |
4 | Site 29 | Phoenix | Arizona | United States | |
5 | Site 15 | Tucson | Arizona | United States | |
6 | Site 3 | Jonesboro | Arkansas | United States | |
7 | Site 22 | Little Rock | Arkansas | United States | |
8 | Site 68 | Carmichael | California | United States | |
9 | Site 55 | Encinitas | California | United States | |
10 | Site 6 | San Diego | California | United States | |
11 | Site 45 | Santa Rosa | California | United States | |
12 | Site 25 | Walnut Creek | California | United States | |
13 | Site 26 | Denver | Colorado | United States | |
14 | Site 1 | Groton | Connecticut | United States | |
15 | Site 54 | Hartford | Connecticut | United States | |
16 | Site 30 | Trumbull | Connecticut | United States | |
17 | Site 34 | Waterbury | Connecticut | United States | |
18 | Site 10 | Aventura | Florida | United States | |
19 | Site 73 | Ft. Myers | Florida | United States | |
20 | Site 51 | Leesburg | Florida | United States | |
21 | Site 49 | Melbourne | Florida | United States | |
22 | Site 64 | New Port Richey | Florida | United States | |
23 | Site 61 | Ocala | Florida | United States | |
24 | Site 27 | Palm Springs | Florida | United States | |
25 | Site 11 | Pinellas Park | Florida | United States | |
26 | Site 75 | Sarasota | Florida | United States | |
27 | Site 69 | St. Petersburg | Florida | United States | |
28 | Site 70 | Venice | Florida | United States | |
29 | Site 17 | West Palm Beach | Florida | United States | |
30 | Site 50 | Alpharetta | Georgia | United States | |
31 | Site 5 | Atlanta | Georgia | United States | |
32 | Site 44 | Decatur | Georgia | United States | |
33 | Site 77 | Douglasville | Georgia | United States | |
34 | Site 9 | Riverdale | Georgia | United States | |
35 | Site 7 | Savannah | Georgia | United States | |
36 | Site 47 | Boise | Idaho | United States | |
37 | Site 24 | Champaign | Illinois | United States | |
38 | Site 20 | Chicago | Illinois | United States | |
39 | Site 76 | Peoria | Illinois | United States | |
40 | Site 58 | Evansville | Indiana | United States | |
41 | Site 39 | Wichita | Kansas | United States | |
42 | Site 59 | Baton Rouge | Louisiana | United States | |
43 | Site 52 | New Orleans | Louisiana | United States | |
44 | Site 53 | Ann Arbor | Michigan | United States | |
45 | Site 63 | Kansas City | Missouri | United States | |
46 | Site 32 | Richmond Heights | Missouri | United States | |
47 | Site 36 | St. Louis | Missouri | United States | |
48 | Site 72 | Billings | Montana | United States | |
49 | Site 21 | Lincoln | Nebraska | United States | |
50 | Site 37 | Reno | Nevada | United States | |
51 | Site 65 | Cary | North Carolina | United States | |
52 | Site 13 | New Bern | North Carolina | United States | |
53 | Site 16 | Winston-Salem | North Carolina | United States | |
54 | Site 60 | Columbus | Ohio | United States | |
55 | Site 67 | Oklahoma City | Oklahoma | United States | |
56 | Site 40 | Tulsa | Oklahoma | United States | |
57 | Site 62 | Eugene | Oregon | United States | |
58 | Site 41 | Medford | Oregon | United States | |
59 | Site 33 | Portland | Oregon | United States | |
60 | Site 18 | Erie | Pennsylvania | United States | |
61 | Site 19 | Philadelphia | Pennsylvania | United States | |
62 | Site 23 | Pottstown | Pennsylvania | United States | |
63 | Site 31 | Anderson | South Carolina | United States | |
64 | Site 35 | Greer | South Carolina | United States | |
65 | Site 4 | Chattanooga | Tennessee | United States | |
66 | Site 74 | Conroe | Texas | United States | |
67 | Site 8 | Corpus Christi | Texas | United States | |
68 | Site 71 | Dallas | Texas | United States | |
69 | Site 42 | Houston | Texas | United States | |
70 | Site 14 | San Antonio | Texas | United States | |
71 | Site 38 | Salt Lake City | Utah | United States | |
72 | Site 28 | Norfolk | Virginia | United States | |
73 | Site 12 | Richmond | Virginia | United States | |
74 | Site 56 | Renton | Washington | United States | |
75 | Site 2 | Seattle | Washington | United States | |
76 | Site 48 | Spokane | Washington | United States | |
77 | Site 43 | Tacoma | Washington | United States |
Sponsors and Collaborators
- Solvay Pharmaceuticals
Investigators
- Study Director: Global Clinical Director Solvay, Solvay Pharmaceuticals
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00141570
Other Study ID Numbers:
- S030.2.106
First Posted:
Sep 1, 2005
Last Update Posted:
Jan 16, 2015
Last Verified:
Jan 1, 2009
Keywords provided by ,
,
Additional relevant MeSH terms: